Stock 3902 MEDICAL DATA VISION CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Medical Data Vision Co., Ltd.

Equities

3902

JP3921250001

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-04-26 am EDT 		5-day change 1st Jan Change
585 JPY -0.68% Intraday chart for Medical Data Vision Co., Ltd. +1.21% -10.69%
Feb. 13 Medical Data Vision Co., Ltd. Provides Dividend Guidance for the Year Ending December 31, 2024 CI
Feb. 13 Medical Data Vision Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2024 CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
  • The group's high margin levels account for strong profits.

Weaknesses

  • The firm trades with high earnings multiples: 22.9 times its 2024 earnings per share.
  • The company appears highly valued given the size of its balance sheet.
  • The company is highly valued given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
MEDICAL DATA VISION CO., LTD. Stock Medical Data Vision Co., Ltd.
-10.69% 142M -
VEEVA SYSTEMS INC. Stock Veeva Systems Inc.
+4.36% 32.47B
C
PRO MEDICUS LIMITED Stock Pro Medicus Limited
+14.14% 7.45B
C-
SECTRA AB Stock Sectra AB
+22.93% 3.89B
B-
EVOLENT HEALTH, INC. Stock Evolent Health, Inc.
-16.29% 3.15B
C-
OMNICELL, INC. Stock Omnicell, Inc.
-25.96% 1.28B
B
LUNIT INC. Stock Lunit Inc.
-36.14% 1.09B -
B-SOFT CO.,LTD. Stock B-SOFT Co.,Ltd.
-35.42% 902M -
SIMULATIONS PLUS, INC. Stock Simulations Plus, Inc.
-0.13% 893M
C
VERADIGM INC. Stock Veradigm Inc.
-24.12% 857M -
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
-
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 3902 Stock
  4. Ratings Medical Data Vision Co., Ltd.